Author: NISREEN M.A. OKBA; Marcel A Muller; Wentao Li; Chunyan Wang; Corine H. GeurtsvanKessel; Victor M. Corman; Mart M. Lamers; Reina S. Sikkema; Erwin de Bruin; Felicity D. Chandler; Yazdan Yazdanpanah; Quentin Le Hingrat; Diane Descamps; Nadhira Houhou-Fidouh; Chantal B. E. M. Reusken; Berend-Jan Bosch; Christian Drosten; Marion P.G. Koopmans; Bart L. Haagmans
Title: SARS-CoV-2 specific antibody responses in COVID-19 patients Document date: 2020_3_20
ID: 9595vm0k_18
Snippet: We performed Anti-SARS-CoV-2 IgG and IgA ELISA using beta-versions of two commercial kits (EUROIMMUN Medizinische Labordiagnostika AG, https://www.euroimmun.com) and performed the assay according to manufacturer's protocol. Reagent wells of both assays are coated with recombinant structural protein (S1 domain) of SARS-CoV-2. The optical density (OD) was detected at 450 nm, and a ratio of the reading of each sample to the reading of the calibrator.....
Document: We performed Anti-SARS-CoV-2 IgG and IgA ELISA using beta-versions of two commercial kits (EUROIMMUN Medizinische Labordiagnostika AG, https://www.euroimmun.com) and performed the assay according to manufacturer's protocol. Reagent wells of both assays are coated with recombinant structural protein (S1 domain) of SARS-CoV-2. The optical density (OD) was detected at 450 nm, and a ratio of the reading of each sample to the reading of the calibrator, included in the kit, was calculated for each sample (OD ratio). As the beta-version of the kit awaits CE validation, we determined an in-house cut-off value based on the mean background reactivity of all SARS-CoV-2-negative sera in the study multiplied by 3. In case of IgA this was OD ratio = 0.9 and for IgG OD ratio = 0.3.
Search related documents:
Co phrase search for related documents- Anti SARS and background reactivity: 1, 2
- Anti SARS and CE validation: 1
- Anti SARS and commercial kit: 1, 2, 3, 4, 5
- Anti SARS and cut value: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- Anti SARS and iga case: 1
- Anti SARS and IgG OD ratio: 1, 2
- Anti SARS and manufacturer protocol: 1
- Anti SARS and OD optical density: 1, 2, 3, 4
- Anti SARS and OD ratio: 1, 2, 3, 4, 5
- Anti SARS and optical density: 1, 2, 3, 4, 5, 6, 7, 8, 9
- Anti SARS and S1 domain: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62
- Anti SARS and SARS sera: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- Anti SARS and structural protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- Anti SARS and study SARS sera: 1
- assay perform and optical density: 1
- assay perform and S1 domain: 1
- assay perform and SARS sera: 1
- background reactivity and cut value: 1
- background reactivity and SARS sera: 1
Co phrase search for related documents, hyperlinks ordered by date